Macro­Gen­ics in­ves­ti­gates three pa­tient deaths in Phase 2 prostate can­cer drug tri­al

Macro­Gen­ics re­port­ed on Thurs­day af­ter­noon that three pa­tients died in a mid-stage tri­al of its an­ti­body-drug con­ju­gate for prostate can­cer. Two par­tic­i­pants died due to pneu­moni­tis and the third died from a pleur­al ef­fu­sion.

The biotech’s shares $MGNX plum­met­ed 66% to $4.91 pre­mar­ket on Fri­day.

A to­tal of five pa­tients died in the tri­al, al­though two of the deaths were deemed un­re­lat­ed to vo­brami­ta­m­ab duo­car­mazine, al­so dubbed vo­bra duo. All but one pa­tient in the tri­al had a treat­ment-emer­gent ad­verse event and 33.5% ex­pe­ri­enced a grade 3 or high­er event.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER